Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer.

Current oncology reports ·Vol. 9 ·No. 6 ·2007-11-00 ·Pages 469-71

Coleman RL

Abstract

暂无摘要

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Coleman Robert L

References (8)

8 references, click to expand

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91 PMID: 15547181
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Gynecol Oncol. 2001 Apr;81(1):3-9 PMID: 11277642
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
Lancet. 2003 Jun 21;361(9375):2099-106 PMID: 12826431
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005340 PMID: 16437527
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.
Ann Oncol. 2001 Aug;12(8):1115-20 PMID: 11583193
Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.
Gynecol Oncol. 2003 Jan;88(1):17-21 PMID: 12504621
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
N Engl J Med. 1996 Jan 4;334(1):1-6 PMID: 7494563
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
J Clin Oncol. 2006 Oct 10;24(29):4699-707 PMID: 16966687

Article Info

Journal

Current oncology reports

Abbr.

Curr Oncol Rep

ISSN

1534-6269

DOI

10.1007/s11912-007-0065-5

Published

2007-11-00

Pages

469-71

Language

English

Region

United States

NLM ID

100888967

Corrections

CommentOn

PMID: 16966687

External Links

PubMed source DOI: 10.1007/s11912-007-0065-5 View journal details

Analysis Services

Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer.

Contact

WeChat Official Account